Lineage Cell Therapeutics’ (LCTX) Buy Rating Reiterated at HC Wainwright

HC Wainwright reiterated their buy rating on shares of Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) in a research note released on Tuesday,Benzinga reports. HC Wainwright currently has a $9.00 price objective on the stock.

Separately, D. Boral Capital upped their price target on shares of Lineage Cell Therapeutics from $2.00 to $3.00 and gave the company a “buy” rating in a research report on Friday, March 6th. Three analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus target price of $5.33.

Lineage Cell Therapeutics Trading Down 1.3%

NYSEAMERICAN LCTX opened at $1.53 on Tuesday. Lineage Cell Therapeutics has a 1 year low of $0.37 and a 1 year high of $2.09. The company has a market cap of $381.11 million, a PE ratio of -5.46 and a beta of 1.74. The stock’s 50-day moving average price is $1.69 and its two-hundred day moving average price is $1.68.

Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) last announced its earnings results on Thursday, March 5th. The company reported $0.00 EPS for the quarter, topping the consensus estimate of ($0.07) by $0.07. The company had revenue of $6.61 million during the quarter, compared to analysts’ expectations of $1.96 million. Lineage Cell Therapeutics had a negative net margin of 436.47% and a negative return on equity of 76.13%. Research analysts forecast that Lineage Cell Therapeutics will post -0.12 EPS for the current fiscal year.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the stock. SG Americas Securities LLC acquired a new stake in shares of Lineage Cell Therapeutics during the 4th quarter valued at $25,000. Citizens Financial Group Inc. RI purchased a new stake in shares of Lineage Cell Therapeutics during the third quarter worth $25,000. Define Financial LLC acquired a new stake in Lineage Cell Therapeutics during the fourth quarter valued at $33,000. DLD Asset Management LP purchased a new position in Lineage Cell Therapeutics in the fourth quarter valued at about $33,000. Finally, Kestra Advisory Services LLC increased its position in Lineage Cell Therapeutics by 174.7% in the 4th quarter. Kestra Advisory Services LLC now owns 27,747 shares of the company’s stock worth $46,000 after purchasing an additional 17,647 shares during the last quarter. Institutional investors and hedge funds own 62.47% of the company’s stock.

About Lineage Cell Therapeutics

Lineage Cell Therapeutics is a clinical-stage biotechnology company developing novel, allogeneic cell therapies built on pluripotent stem cell platforms. The company focuses on three primary therapeutic areas—retinal disease, neural repair and immune-effector cell oncology—leveraging its proprietary manufacturing processes to create off-the-shelf cell therapy candidates designed for broad patient populations.

Its lead candidate, OpRegen, comprises retinal pigment epithelium cells intended to slow or reverse vision loss in patients with geographic atrophy secondary to age-related macular degeneration.